Partnering Culture
Partnering Culture
Search
Boehringer Ingelheim appointment to Board Managing Directors
Boehringer Ingelheim announces appointments to Board of Managing Directors
A lifetime for patients with mental health conditions
Chris Underhill is a social entrepreneur and participant at the Making More Health Convention.
Meet our team
Meet our team
Animal Health
Animal Health
Careers: Winning with people
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
Sustainable Development - Our Commitment
Our Commitment
Trends & Insights
Trends & Insights
Science Focus
Science Focus
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
Production Insights
Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
Therapeutics
Therapeutics
Meet the Partnering Team Video 2023
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
EASi-KIDNEY™ Phase III trial for people with CKD
Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
Metabolic Diseases
Metabolic Diseases
History video
Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
EFPIA Mission Possible
This new video highlights how treatments once known for type 2 diabetes are now helping to prevent heart failure, stroke or kidney disease.
EASi-HF™ Phase III trial in patients with HFpEF
Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
Heart Diseases
Heart Diseases
Sites Around the World
Sites Around the World
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership